Tissue Transglutaminase IgA (TTG)
Immunity0 parametersReport in 4HrsAt Home
No Fasting Required
Details
Detects IgA antibodies against tissue transglutaminase, an enzyme involved in the autoimmune response in celiac disease
₹399₹1,210
67% OFF
FREE:AI Insights
Tissue Transglutaminase IgA (TTG) - Comprehensive Medical Test Guide
- Section 1: Why is it done?
- Test Purpose: The TTG IgA test measures immunoglobulin A (IgA) antibodies against tissue transglutaminase, an enzyme found in the small intestine. These antibodies are produced by the immune system when it reacts to gluten in patients with celiac disease.
- Primary Indications: Screening for celiac disease in symptomatic patients • Investigating chronic gastrointestinal symptoms (diarrhea, abdominal pain, bloating) • Evaluation of malabsorption syndromes • Assessment of dermatitis herpetiformis (DH) • Screening family members of diagnosed celiac disease patients • Evaluation of unexplained iron deficiency or anemia • Investigation of failure to thrive in children • Assessment of osteoporosis risk factors
- Typical Timing and Circumstances: Performed when patients present with symptoms suggestive of celiac disease • Initial screening test in primary care settings • Before intestinal biopsy if TTG results are positive • As part of comprehensive autoimmune disease workup • In patients with unexplained nutritional deficiencies • When other autoimmune conditions are present (type 1 diabetes, thyroid disease) • During evaluation of chronic fatigue or neurological symptoms
- Section 2: Normal Range
- Reference Range Values: Negative/Normal: < 2.0 U/mL or < 1.0 U/mL (varies by laboratory) • Weak Positive: 2.0-10 U/mL • Positive: 10-100 U/mL • Strong Positive: > 100 U/mL
- Units of Measurement: U/mL (Units per milliliter) or Arbitrary Units (AU/mL) - reference ranges vary by laboratory assay used
- Result Interpretation: Negative Result: No detectable TTG IgA antibodies; celiac disease is unlikely but not completely ruled out • Weak/Borderline Positive: May indicate early celiac disease, gluten sensitivity, or false positive; further testing recommended • Positive Result: Suggests active celiac disease with high sensitivity (95-98%); intestinal biopsy typically recommended for confirmation • Strong Positive: Highly indicative of celiac disease; biopsy confirmation usually recommended before dietary changes
- What Normal vs. Abnormal Means: Normal: Immune system is not mounting an attack against tissue transglutaminase; celiac disease is unlikely • Abnormal: Indicates presence of anti-TTG IgA antibodies produced in response to gluten exposure; highly specific for celiac disease diagnosis
- Section 3: Interpretation
- Detailed Result Interpretation: Negative TTG IgA: Celiac disease very unlikely; patient does not have typical celiac disease • Weak Positive (2-10 U/mL): Consider repeat testing, evaluate IgG antibodies in IgA-deficient patients, may need intestinal biopsy • Moderate Positive (10-100 U/mL): Strong evidence of celiac disease; biopsy recommended • Strong Positive (>100 U/mL): Very high likelihood of celiac disease; intestinal changes almost certainly present
- What Different Results Indicate: Positive Results: Active celiac disease with intestinal immune response to gluten; patient should avoid gluten-containing foods • Negative Results with Symptoms: May indicate non-celiac gluten sensitivity, other gastrointestinal disorders, or very early disease; consider repeat testing or additional diagnostic workup • Results in Context: Must be interpreted with clinical symptoms, serum IgA levels, and intestinal biopsy findings
- Factors Affecting Results: Gluten Consumption: Test must be performed while patient is consuming gluten; false negatives occur on gluten-free diet • IgA Deficiency: 2-3% of celiac patients have total IgA deficiency; requires IgG antibody testing instead • Disease Activity: Antibody levels correlate with intestinal damage; may decrease with gluten avoidance • Assay Variation: Different laboratory methods may yield different cutoff values • Time from Symptom Onset: Very early disease may show negative results • Age: Antibody production may be lower in young children or elderly patients
- Clinical Significance of Result Patterns: TTG Positive + Endomysial Antibody (EMA) Positive: Confirms celiac disease with near 100% specificity • TTG Positive + EMA Negative: Unusual; may represent early disease or technical error; repeat testing recommended • TTG Negative + Clinical Symptoms: Consider non-celiac gluten sensitivity, repeat testing, or evaluate other conditions • Rising Antibody Titers: Indicates ongoing gluten exposure or inadequate dietary adherence • Falling Antibody Titers: Suggests good adherence to gluten-free diet and intestinal healing
- Section 4: Associated Organs
- Primary Organ System Involved: Small Intestine (Primary): Duodenum and jejunum are primary sites of gluten-induced immune damage • Immune System: Adaptive and innate immune response in gut mucosa • Associated Secondary Systems: Gastrointestinal tract, bone metabolism, nervous system, reproductive system
- Medical Conditions Associated with Abnormal Results: Celiac Disease: Autoimmune disorder causing intestinal mucosal damage • Dermatitis Herpetiformis: Skin manifestation of celiac disease with GI involvement • Refractory Celiac Disease: Persistent symptoms despite strict gluten-free diet • Non-Celiac Gluten Sensitivity: May show positive TTG in some cases • Gastrointestinal Dysfunction: Malabsorption, nutrient deficiencies
- Diseases This Test Helps Diagnose or Monitor: Celiac Disease: Primary diagnosis; test has 95-98% sensitivity in patients on gluten-containing diet • Associated Autoimmune Conditions: Type 1 diabetes, thyroid disease, Sjögren's syndrome • Malabsorption Syndromes: Iron deficiency anemia, vitamin B12 deficiency, folate deficiency • Dermatitis Herpetiformis: Gluten-dependent skin disease with intestinal pathology • Monitoring Response to Gluten-Free Diet: Serial testing tracks intestinal healing and immune response
- Potential Complications Associated with Abnormal Results: Intestinal Complications: Villous atrophy, malabsorption, increased intestinal permeability • Nutritional Deficiencies: Iron, vitamin B12, folate, calcium, vitamin D deficiency • Bone Health: Osteoporosis and increased fracture risk from malabsorption • Neurological: Ataxia, peripheral neuropathy, seizures in some patients • Reproductive: Infertility, miscarriage, adverse pregnancy outcomes if untreated • Increased Malignancy Risk: Intestinal lymphoma if celiac disease untreated for extended periods • Associated Autoimmune Conditions: Higher risk of developing other autoimmune diseases
- Section 5: Follow-up Tests
- Additional Tests Recommended Based on Results: If TTG IgA Positive: Endomysial Antibody (EMA) test for confirmatory specificity • If TTG IgA Negative with High Clinical Suspicion: Total serum IgA level to rule out IgA deficiency; if deficient, test TTG IgG and EMA IgG • If TTG IgA Positive: Tissue transglutaminase IgG if patient has selective IgA deficiency • For All Cases: Human leukocyte antigen (HLA-DQ2/DQ8) testing if serological results uncertain
- Further Investigations if Positive: Upper Endoscopy with Duodenal Biopsy: Gold standard for confirming celiac disease diagnosis • Intestinal Biopsy: Demonstrates villous atrophy, crypt hyperplasia, and intraepithelial lymphocytes • Complete Blood Count: Assess for anemia from malabsorption • Iron Studies: Serum iron, ferritin, total iron-binding capacity • Vitamin B12 and Folate Levels: Evaluate for nutritional deficiencies • Tissue Transglutaminase IgG: In IgA-deficient patients • Anti-Endomysial Antibody IgG: In IgA-deficient patients
- Monitoring Frequency for Ongoing Conditions: Initial Diagnosis: TTG and EMA testing at time of diagnosis • After Starting Gluten-Free Diet: Repeat TTG IgA at 6-12 months to assess dietary adherence and intestinal healing • Annual Monitoring: Yearly TTG testing in first 1-2 years to confirm sustained remission • Long-term Follow-up: Every 1-2 years or if new symptoms develop • If Antibodies Remain Elevated: Repeat testing at 6 months; consider patient education on gluten avoidance • When Symptoms Persist on Gluten-Free Diet: Retest TTG IgA; investigate refractory disease or other conditions
- Related Tests Providing Complementary Information: Endomysial Antibody (EMA): Higher specificity (98-100%) but lower sensitivity than TTG • Deamidated Gliadin Peptide (DGP) IgA and IgG: Alternative serological markers • Total Serum IgA: Necessary to interpret TTG results; helps identify IgA deficiency • HLA-DQ2 and HLA-DQ8: Genetic markers; present in >99% of celiac patients • Thyroid Peroxidase (TPO) Antibodies: Screen for associated thyroid disease • Tissue Transglutaminase IgG: Used when total IgA is deficient • Anti-Endomysial Antibody IgG: Confirmatory test in IgA-deficient patients
- Section 6: Fasting Required?
- Fasting Requirement: No - Fasting is NOT required for this test
- Patient Preparation Requirements: General Preparation: Standard venipuncture; no special preparation needed • Patient can eat and drink normally before test • No restrictions on daily activities before blood draw • Comfortable, loose-fitting clothing recommended for easy blood draw access
- Critical: Gluten Consumption Before Testing: IMPORTANT: Patient should be consuming gluten-containing foods for accurate results • Test should be performed BEFORE starting a gluten-free diet • If patient has already started gluten-free diet, false negative results are likely • Patient may need to reintroduce gluten (2 slices of bread daily) for 4-6 weeks before testing if on gluten-free diet • Discuss timing with healthcare provider to ensure proper test interpretation
- Medications to Avoid: No medications need to be stopped or avoided for this test • Immunosuppressive medications may theoretically affect antibody levels but should not be discontinued without medical guidance • All current medications should be continued as prescribed • Inform healthcare provider of all medications being taken, especially immunosuppressants or biologics
- Special Instructions: Collection Method: Simple blood draw via venipuncture into serum separator tube • Timing: Can be performed at any time of day • Sample Handling: Serum is separated from blood cells and tested • Results Timing: Typically available within 1-3 business days depending on laboratory • Patient Information: Bring valid identification and insurance information to laboratory
How our test process works!
